We perform ed a retro spective chart review to catego rize a group ofpetrous apex fi ndings that were noted incid entally on magn etic resonan ce ima gin g (MRl) in 88 patients. These patients were among those who had been seen at a tertiary care center between July 1988 and July 1998. These inci dentalfindin gs, which were unrelat ed to the presentin g clinical manifestations , included asymmetric f atty bone marrow (n = 41), infl ammation (19), cholestero l granulomas ( 14), cholestea tomas (9) , and neopla sms (5) . Foll owup imagin g and clinical surveillance of these patients has not demonstrated any significant change in the incid entally detected lesions. In all cases, the incidental MRI fi ndings represented benign path ology.
Introduction
Th e petrou s apex can be the site of a va riety of path ol ogic conditio ns . Th e nature of these condition s ranges fro m inflammatory to neopl astic, and lesion s can arise fro m the petrous bon e itself or from adj acent neurovascular structure s.' An accura te dia gn osis is dep endent on the patient ' s histor y, ph ysical ex amination, and find ings on magnetic resonance im aging (M RI) and computed tom ograph y (CT). Th e im aging fe atures are key , and the need for surg ica l int ervention sho uld be based on the corr el at ion of imag ing and cl in ical findings .
Th e pu rpose of our study was to categorize a group of petrou s ape x radiographic findings that were incidentall y noted on MRI in patients wh o we re und er goin g d iagnostic testing fo r a va riety of he ad and nec k sy mpto ms .
Materials and methods
We identified 88 patients-52 fe ma les and 36 mal es, aged 16 to 7 1 ye ars (mean: 39 .8)-with pet rou s apex les ion s that had been incid ent all y noted on MRI at our institution bet we en Jul y 1988 and Jul y 1998. From a retrospe cti ve review of pati ent rec ord s and othe r reports, we obt ained informatio n on the indicati on s for each MRI , the incidental findin g, and the long-term outco me . Histol ogic dat a we re also obta ined on the fe w pati ent s who required surg ica l inter venti on (n =8) or biopsy (I) .
Indications for MRI (signs and symptoms). Sevent y-
five of the 88 patie nts had no presenting signs (table) . A mo ng those who did , the most common were tr ismu s and decreased fa cia l se ns itiv ity. which alt ogeth er we re obse rve d in only 10 pati ent s. Th e most common pre senting sy mpto ms we re he ada ch e and fa cia l pain (table) . Th e distr ibuti on of the se signs and sy mp to ms wa s in no way related to the d istributi on of the incid ental find ings on MRI.
Incidental findings. Fort y-one pati ent s were noted to have an asy m me tr ic enha nce me nt of bon e marrow in the petrou s ape x, and 19 pat ient s dem on strated asymmetric inflammation. Fou rteen had small ch ol esterol gra nulomas, 9 had asy mpto ma tic cho les tea to mas, and 5 had neoplasm s (2 menin giomas, 2 trigeminal ner ve neuroma s, and I os teo b las to ma) .
Outcom es. Eight of the 88 patient s had their lesion s surgically excised (4 ch ole steatomas, 2 cho les terol gra nulom as, and 2 neopl asm s). Th e surgica l approac hes used to ac hieve skull base access to the pet ro us apex in the 8 operated patient s we re an orbitocraniozygoma tic app roach in 4 pati ent s, a middl e fossa approach in 2, and a tran smastoid approach in 2.
The MRI surveillance prot oc ol for the 80 patients who had not und er gon e surgery ( I of these pati ent s did under go a CT -guided biop sy) included rep eat studies at 1-, 3-, and 5-year int er val s.
A1l41 patient s who had asy mme tric bon e marrow in the petrou s apex showed no cha nge on imaging ove r tim e. Of the 19 patient s with inflammator y ch an ges, 2 ex hibited an incre ase in signa l int en sit y over tim e, 6 had a decrease in New Techniques in ENT: Specialty Instruments for APC TIvI and Electrosurgery
The nasal turbinates are effectively reduced long-term in hyperplasia ( Fig. 1 ).
APC permits non-contact, homogeneous and highly effective treatment of superficial lesions of the oral mucosa such as granuloma and leukoplakia ( Fig. 2 ).
APC's limited penetration depth offers maximum protection against perforation in treatments of papillomatosis ( Fig. 3 ).
Telangiectatic lesions in the nasal mucosa can be treated as well as lesions in the skin and mucosa of the lips and oral cavity ( Fig. 4 ).
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The True Blue Probe for Argon Plasma Coagulation
Over 160YearsWorld-Leading Medical Technology APC (Argon Plasma Coagulation) permits safe hemostasis and effective devitalization of pathologic tissues. Speciallydeveloped instruments now make the advantages of APC, along with ERBE electrosurgical technology, available for ENT: inflammation , and 11 were unchanged . Of the 12 patients with cholesterol gran ulomas , 4 showed an increase in the size of their lesion s, none had a decrease in size, and 8 were unchanged. Of the 5 patients with cho lesteatomas , 2 showed an increase and 3 were unchanged. Finally, all 3 of the neopl asms followed with MRI (which included selec ted coronal cuts with gadolini um enha ncement) showed a slight increase in size. In all of these 80 patients, follow up MRI found increases in 11, decreases in 6, and no cha nge in 63 . None of the 11 increases was significant enough to warrant surgical inter ven tion .
Discussion
The petrous portion of the temporal bo ne is a pyramidshaped structure tha t extends med ially and anteriorly toward the ce ntra l sk ull base . Th e core of the petro us bo ne houses the labyrinth , cranial nerves VII and VIII, the internal carotid artery, and the j ugul ar bulb. The petro us apex varies in its degree of pneumatization, but it includes the peri tubal and apical air cell tracks.' Th e per ituba l region surro unds the eus tachian tub e and is anterolate ral to the carotid ca nal. The apical area is posteromedial to the carotid canal. Th e degree of petrou s apex pneumatiza tion is often asymmetric , and the presence of air cells in this region can predispose the petro us apex to inflammatory diseases.
Th e clin ical manifestations of petrous apex disease ca n be subtle or nonexistent. Adva nced lesions in this area ca n ca use a mass effect, bone erosion, or inflam mation with a res ultant dysfun ction of the adjacent cra nial nerves III through VIII. Patient s might report headache, eye pain , ota lgia , diplopia, facia l twitch ing, unsteadiness, hearing 20 2 loss, or otorr hea .' Small lesions of the pe trous apex are usually asy mpto matic .
Diagn ostic imagin g. Specific petrous apex pathology can be diagnosed only wit h appropriate diag nostic imaging . CT is ideal for evaluating bony anatomy and bone des truc tion , whereas MR I is more specific for eva luating soft tissue and neurovascular anato my.' MR I with intravenous gado lini um enhancement is also imp ortant to identify the presence and extent of neop lasms in this region (fig ure 1 ). MRI ca n differentiate lesions based on the vario us signal intensities of the different weig hted images. Fast spin-echo tec hniques can add reso lutio n to MR Is, and fat-suppression techn iques distinguish adipose tissue from patho logy .' Pathology. A variety of pathologic processes ca n involve the petro us apex . Th ey can be classified as an intrin sic lesion or as a secondary invasion from an adj acent neurova scular structure. Infl amma tion of the petrous apex ca n be caused by apical air ce ll effusion or by the mo re adva nced skull base osteo mye litis. CT findings in the case of inflammatio n generally incl ude opacification of air cells, while MRI sig nals are hyperint en se on T 1weig hted (T IW) and T2-weight ed (T2W) images (figure 2) . Simple fluid effus ions can become infected and lead to bac terial petrou s apicitis , osteo myel itis, or chron ic obstruction, which in turn can lead to the formation of petrous apex mucoceles.
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Neonate~andinfants aged< 12 weeks f3 months! Due to incompletelydevelopedrena l function affectingamoxicillin eliminat ionin thisagegroup. therecommended dose of Augmentlnis 30mg !kg/day. div ided ql 2h. based on theamoxicillin component. Clavulanate elimi nationis unalteredin this age group. Experience with the200 mg/5mLformulation inthisage group is limited, andthus, use of the125 mg/5 mLoral suspension is recommended. Petrous ape x ch ole steatoma, whic h is belie ved to arise from co nge nita l epithe lial rests, ca n lead to the acc umulati on o f epithe lial ce lls." A cho les tero l granuloma , on the othe r hand , is ca use d by pet rou s apex mu cosal hem orrhage, obs truction, and inflammation, which ca n lead to the for mat ion of a th ick, fl uid-filled, hem orrh agic cys t wit h a su rro unding fibrou s ca psule." Both cho les tea to mas and cho les terol granulomas ca n rema in clinic ally si lent for several years, Wh ile CT shows bon e erosion in both lesion s, the MRI features are more spec ific. On MRI , ch olesteatom as are hypoi nten se with respect to brai n tissue on T1W images and hyperintense on T2W images ( figure 3 ). Cholesterol gra nulom as are typically hyperin tense on both T l Wand T2W images ( figure 4) . Surgical extirpation is the recommended trea tment for petrou s apex cholesteatomas, while surgica l excision or surgical drainage with interna l stenting is ofte n recommended for the management of cho lesterol gran ulomas .
Pet ietns eoeo12week" 13 months)andolder
The most com mon vascu lar lesions of the petrous apex include ane urys ms, arteriovenous malformations, and caro tid cave rno us fistulae." All of these lesions can be identified on contrast -enhanced CT, MRI, or magnetic resonance angiography. However, the most acc urate diagnosis and poss ible endovascular trea tme nt might involve inter ventional angiography .
Primary neoplasms of the petrous apex inc lude meningiom as, trigemi nal neuromas , chordomas, and chondrosarco mas." Arach noida l cysts , which are not true neoplasms , can also invo lve the petrous apex and cause symptoms that mimi c neoplasms in this regio n. Metastatic petrous apex neoplasms are extremely rare, but some have been reported to have spread from distant sites such as the breast, lung, prostate, thyroid, and kidney. 10 Fibrous dysp las ia can involve the petrous apex as well as other portions of the tempo ral bone." On CT , a find ing compatible with fibrous dysplasia has the characteristic "ground gla ss" appearance. Perhaps the most common confounding element in diagnosing pathology in the petrous apex by CT or MRI is asymmetry of the bone marrow because it can mimic several of the lesions discussed above ( figure 5 ).
206 Figur e 5. Axial-view Tl W MR I shows slightly asymmetric bone mar row ill the petrous ap ex (arrow).
